News and Events

New clinical trial recruits the immune system to attack chronic lymphocytic leukemia

Chronic lymphocytic leukemia (CLL) is cancer that develops in blood-forming cells in the bone marrow. A new clinical trial is testing a way to boost the body’s natural immune cells and recruit them to attack and kill marked leukemia cells.

Samples from acute myeloid leukemia patients with the splicing factor mutation

CCR researchers discover how protein translation disruptions can lead to cancer

A mutation in the gene U2AF1, which codes for a protein involved in cutting out key pieces of RNA, can also have widespread effects on the translation of messenger RNA into proteins. A close look at one affected protein, interleukin 8 (IL8), revealed increased production as a result of the mutation, leading to inflammation and cancer spread.

Drug found effective in mice for uveal melanoma

Drugs that directly target the transcription factor YAP, which is associated with the growth of uveal melanoma, are too toxic to be used in patients. A new study in mice, however, finds a new, safe and effective way for targeting the YAP pathway.

Elaine Jaffe inducted as honorary fellow of the Royal College of Pathology of Australasia

Elaine Jaffe, M.D., Senior Investigator in the Laboratory of Pathology, was recently inducted as an honorary fellow of the Royal College of Pathology of Australasia. The fellowship recognizes the work and publications of a haematophathologist that have influenced and improved haematopathology practice worldwide.

CCR Presentations at AACR - 2019

The American Association for Cancer Research (AACR) Annual Meeting covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions all over the world. The 2019 AACR Meeting, "Integrative Cancer Science • Global Impact • Individualized Patient Care", will be held in Atlanta, between March 29 - April 3, 2019. View the list of CCR presentations...

From father to daughter: A bone marrow transplant for GATA2 deficiency

James and Jahleel are a father-daughter duo from Tennessee who came to NIH for Jahleel’s bone marrow transplant. Jahleel was diagnosed with GATA2 deficiency, a rare genetic disease that causes a wide range of symptoms, including myeloid leukemias.

Deep-imaging study reveals extensive variability in 3D configuration of genomes between cells

A new study analyzing chromatin in single cells using advanced imaging methods, led by CCR Director Tom Misteli, Ph.D., has revealed more heterogeneity in the 3D configuration of genomes than previously thought.

New strategy for treating brain tumors with mutations in metabolic enzymes

Cancers with mutations in key metabolic enzymes disrupt oxygen metabolism and cause a buildup of reactive oxygen species in mice. This mutation is found in about 80 percent of grade II/III gliomas, or brain tumors, in humans. By inhibiting the action of a protein that allows cancer cells to survive, investigators have potentially found a new strategy for treating cancers with these mutations.

Recap: Grand Rounds with Felicia Knaul, Ph.D.

Nearly 200 CCR staff attended a special Grand Rounds lecture this month featuring Felicia Knaul, Ph.D., an expert in palliative care. Dr. Knaul, a professor at the Leonard M. Miller School of Medicine and Director of the University of Miami Institute for Advanced Study of the Americas, discussed the unequal access to pain and palliative care around the world, particularly related to morphine for pain relief, and the critical importance of educating providers.The lecture, held February 1, was sponsored by CCR’s Women Scientist Advisors (WSAs).

A scanning electron micrograph of a T lymphocyte

Researchers identify a key molecule that enhances T cell-based immunotherapy

The transcription factor c-Myb plays a critical role in regulating T cell stemness. Researchers showed that increasing expression of this transcription factor in T cells launches a powerful, long-lasting antitumor response in mice.

Breadcrumb